1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
ScinoPharm Taiwan, Ltd.

ScinoPharm Taiwan, Ltd.

1789.TW
ScinoPharm Taiwan, Ltd.TW flagTaiwan Stock Exchange
20.90
TWD
+0.10
- -
16.53BMarket Cap
ScinoPharm Taiwan, Ltd.
1789.TW
(Taiwan Stock Exchange)

Recent

price

20.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.39
5.13
5.78
6.43
5.18
5
5.1
4.45
4.46
3.66
3.9
3.49
4.13
4.03
4.31
- -
3.79
Revenue per Share
1.44
1.24
1.48
1.61
0.61
0.8
0.83
0.53
0.56
0.27
0.36
0.31
0.45
0.36
0.43
- -
0.24
Basic EPS, GAAP
1.61
0.63
0.13
-0.39
-0.17
0.48
1.53
0.71
1.4
0.86
0.97
0.24
0.66
-0.07
0.58
- -
0.28
Free Cash Flow per Basic Share
- -
0.08
0.8
0.99
1.03
0.18
0.28
0.29
0.48
0.49
0.27
0.5
0.48
0.36
0.3
- -
- -
Dividend per Share
8.56
9.44
9.78
10.56
9.68
10.25
10.71
10.88
10.9
10.62
10.83
10.83
10.72
10.63
10.61
- -
9.76
Book Value per Share
9.17
11.09
11.45
12.16
11.83
12.44
12.9
13.14
13.31
12.96
13.3
13.28
13.2
13.08
13.29
- -
12.18
Tangible Book Value per Share
722
771
791
791
791
791
791
791
791
791
791
791
791
791
791
- -
842
Basic Weighted Avg Shares
3,891
3,954
4,573
5,088
4,098
3,955
4,031
3,516
3,524
2,893
3,083
2,762
3,264
3,186
3,406
3,163
3,195
Sales/Revenue/Turnover
31.42
28.67
27.55
27.47
13.65
18.95
21.54
15.9
15.84
9.23
12.18
10.45
12.43
9.87
9.47
3.44
6.82
Operating Margin (%)
367
348
363
448
469
483
445
433
406
409
393
382
439
461
488
517
502
Depreciation Expense
1,040
959
1,171
1,273
484
635
659
422
443
217
282
243
353
287
339
137
205
Net Income, GAAP
13.03
15.33
14.67
9.59
19.61
20.91
18.74
11.14
9.7
18.26
21.32
19.46
19.35
17.71
17.84
7.07
18.77
Effective Tax Rate (%)
26.73
24.27
25.61
25.03
11.81
16.05
16.34
12.01
12.57
7.49
9.15
8.81
10.82
9.01
9.96
4.33
6.41
Profit Margin (%)
3,483
4,991
4,854
4,369
3,332
3,758
4,894
5,352
4,561
4,665
5,229
5,410
5,517
5,651
5,840
4,781
4,596
Working Capital
- -
- -
- -
- -
- -
- -
771
1,098
- -
590
550
540
581
570
620
609
617
LT Debt
6,677
8,567
9,071
9,643
9,380
9,857
10,228
10,417
10,539
10,260
10,529
10,511
10,450
10,364
10,526
10,525
10,268
Total Equity
17.95
12.46
11.81
12.64
4.25
5.31
5.93
4.09
4.17
1.9
2.67
2.08
2.93
2.32
2.38
0.9
1.6
Return on Invested Capital (%)
18.51
14.22
15.33
15.03
5.42
6.85
6.86
4.77
5.07
2.74
3.22
2.72
3.94
3.24
3.83
1.61
2.37
Return on Capital (%)
19.56
14.26
15.6
15.84
6.05
8.06
7.95
4.95
5.15
2.55
3.33
2.84
4.15
3.4
4.04
1.64
2.48
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
56
76
107
LT Borrowings
- -
- -
- -
LT Finance Leases
620
621
617
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
791
791
791
Market Capitalization
18,473
17,518
14,311

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
6,608
5,536
5,656
Cash, Cash Equivalents & STI
4,166
3,098
3,093
Accounts Receivable, Net
604
447
494
Inventories
1,673
1,792
1,896
Total Current Liabilities
768
735
1,060
Payables & Accruals
- -
- -
- -
ST Debt
56
76
107
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.67%
- -
-0.01%
Free Cash Flow
-76.82%
-201.06%
-35.16%
Net Income, GAAP
-7.69%
-5.75%
-59.64%
Sales/Revenue/Turnover
-1.68%
1.03%
-7.13%
Total Cash Common Dividend
13.98%
11.24%
16.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
648
755
660
1,123
3,186
2024
883
762
724
1,036
3,406
2025
686
748
1,008
- -
3,163

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.05
0.07
0.04
- -
0.36
2024
0.18
0.09
0.03
- -
0.43
2025
0.06
0.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.36
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
- -
Similar Companies
Silver Spike Investment Corp. (SSIC)
Alembic Pharmaceuticals Limited (APLLTD.NS)
Shanghai Jiaoda Onlly Co.,Ltd (600530.SS)
Evotec SE (EVT.DE)
CordovaCann Corp. (CDVA.CN)
Albert David Ltd. (ALBERTDAVD.BO)
Business
ScinoPharm Taiwan, Ltd. (1789.TW) researches, develops, manufactures and sells active pharmaceutical ingredients, injectable drug products and contract development and manufacturing organization services to global pharmaceutical companies. The company offers small molecule APIs, peptide APIs, high potency APIs, protein drugs, complex natural molecules and derivatives, biochemistry molecule synthesis services including peptides and nucleic acids, generic API manufacturing, custom process research and manufacturing, CRAM services encompassing chemistry, analytical, regulatory and consulting support, end-to-end CMC solutions from preclinical to commercial stages, western medicines, chemical materials, albumin and oligonucleotide medicines, and injectable formulations primarily focused on oncology, CNS and cardiovascular therapeutic areas; it operates cGMP facilities with 18 flexible production lines. ScinoPharm Taiwan serves generics and innovative drug makers across Taiwan, rest of Asia including China via subsidiary ScinoPharm Changshu, Europe, the United States, India and emerging markets, with over 950 DMFs filed in more than 100 countries, facilities approved by FDA, EMA, PMDA, TFDA and ANVISA. Founded in 1997 and headquartered in Tainan City, Taiwan, the company pursues a Double-A strategy for global expansion. Recent developments include strategic investment and partnership with Handa Pharmaceuticals to advance 505(b)(2) drug development through shared R&D, clinical trials and commercialization; zero-deficiency US FDA inspections for its injectable plant and China subsidiary in 2024; zero-deficiency ANVISA inspection enhancing emerging market presence; strong H1 2025 financials with NT$1.434 billion revenue amid injectable and CDMO growth; 2024 full-year revenue of NT$3.406 billion up 7% and net profit up 18%; and ongoing expansion into formulation development and CDMO businesses.